Jordan Woodard

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 25% of the U.S. adult population. MASLD can progress to fibrosis, cirrhosis and hepatocellular carcinoma if left untreated. Therefore, MASLD fibrosis screening is encouraged for at risk populations…